How Ozempic Compares to Other GLP-1 Drugs for Weight Loss and Diabetes
Ozempic (semaglutide) from Novo Nordisk leads in weight loss efficacy among GLP-1 receptor agonists, with clinical trials showing 15-20% body weight reduction over 68 weeks at 2.4 mg weekly doses, outperforming older options like Victoza (liraglutide) at 5-10% [1][2]. For type 2 diabetes control (A1C reduction), it delivers 1.5-2% drops, similar to Trulicity (dulaglutide) but better than Byetta (exenatide) at 0.8-1.2% [1][3].
Wegovy vs. Ozempic: Same Drug, Different Doses and Approvals
Wegovy is higher-dose semaglutide (up to 2.4 mg) approved solely for obesity, achieving 15% average weight loss in STEP trials vs. Ozempic's 2.0 mg diabetes dose at 10-12%. Both share cardiovascular benefits, reducing major events by 20-26% in heart patients [2][4].
Mounjaro and Zepbound: Tirzepatide Edges Out Semaglutide
Eli Lilly's tirzepatide (Mounjaro for diabetes, Zepbound for weight loss) combines GLP-1/GIP action, yielding 21% weight loss in SURMOUNT trials vs. Ozempic/Wegovy's 15%, and 2.3% A1C reduction vs. 1.9% [5][6]. Head-to-head SURPASS-2 trial confirmed tirzepatide superior for both metrics [5].
| Drug | Weight Loss (68 weeks, %) | A1C Reduction (%) | Weekly Dose |
|------|---------------------------|-------------------|-------------|
| Ozempic/Wegovy (semaglutide) | 15-20 | 1.5-2.0 | 0.25-2.4 mg |
| Mounjaro/Zepbound (tirzepatide) | 20-22 | 2.0-2.3 | 2.5-15 mg |
| Trulicity (dulaglutide) | 8-12 | 1.4-1.6 | 0.75-4.5 mg |
| Victoza (liraglutide) | 5-8 | 1.0-1.5 | 0.6-3.0 mg daily |
Data from SUSTAIN, STEP, SURMOUNT, and SURPASS trials [1][2][5].
Why Semaglutide Wins on Heart Protection but Lags in Speed of Loss
Ozempic reduces heart attacks, strokes, and death by 26% in SELECT trial patients with obesity (no diabetes), a first for weight loss drugs. Tirzepatide shows similar promise in ongoing trials but lacks full data yet [4][7]. Semaglutide acts slower initially but sustains loss better long-term without dose escalation issues seen in some rivals.
Side Effects and Dropout Rates Across the Board
All cause nausea (20-40%), vomiting (10-20%), and diarrhea, but tirzepatide has higher GI rates leading to 7-10% dropouts vs. semaglutide's 5-7% [5][6]. Rare pancreatitis and gallbladder risks apply equally; semaglutide links to slight thyroid tumor risk in rodents, not confirmed in humans [1][3].
Cost and Access: Why Effectiveness Isn't Everything
Monthly costs range $900-1,300 without insurance; Wegovy/Mounjaro often pricier due to demand. Compounded semaglutide versions cut costs to $200-400 but face FDA scrutiny for safety [8]. Patents on Ozempic expire 2031-2032 in the US, delaying generics [9].
Sources
[1]: NEJM - SUSTAIN Trials
[2]: NEJM - STEP 1 Trial
[3]: ADA Guidelines
[4]: NEJM - SELECT Trial
[5]: NEJM - SURPASS-2
[6]: NEJM - SURMOUNT-1
[7]: Lilly Trial Updates
[8]: FDA Compounding Alert
[9]: DrugPatentWatch - Ozempic